Science news

<<  return



European Society of Cardiology 2014 Congress: We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more. The addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes.